[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640292":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":10,"responsibleParty":25,"collaborators":10,"id":27,"slug":10,"hasResults":28,"nctId":29,"briefTitle":30,"officialTitle":31,"acronym":10,"eligibilityCriteria":32,"healthyVolunteers":28,"sex":33,"minAge":34,"maxAge":35,"enrollmentInfo":36,"targetDuration":39,"studyType":40,"phases":10,"briefSummary":41,"conditions":42,"keywords":10,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":10},{"fullName":5,"class":6},"TG Therapeutics, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Long-term Follow-up",null,"Participants who received azer-cel in TG-Azercel -101 study will be followed-up for a total of 15 years until withdrawal of consent, lost to follow-up, or until death.",[13],"Other: No Intervention",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":10},"OTHER","No Intervention",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"TG Therapeutics Clinical Support Team","CONTACT","1-877-575-8489","clinicalsupport@tgtxinc.com",{"type":26,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100640292",false,"NCT07577583","Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel","Long-term Follow-up (LTFU) of Study Participants Who Received Azer-Cel, An Allogeneic Chimeric Antigen Receptor T-Cell Product, in a TG Therapeutics, Inc., Clinical Study","Inclusion Criteria:\n\n1. Received at least 1 dose of azer-cel in TG-Azercel -101 study.\n2. Signed informed consent form (ICF).\n3. Willingness and ability to adhere to the study schedule and all other protocol requirements.\n\nExclusion Citeria:\n\n1\\. No unique exclusion criteria apply to this study.","ALL","18 Years","62 Years",{"count":37,"type":38},32,"ESTIMATED","15 Years","OBSERVATIONAL","The main objective of this study is to collect data on the long-term safety of azer-cel, primarily through the capture of clinical events of interest (CEI) for up to 15 years following participation in TG-Azercel -101 study.",[43],"B-cell Mediated Autoimmune Disorders","NOT_YET_RECRUITING","2026-05-05",{"date":47,"type":48},"2026-05-11","ACTUAL",{"date":50,"type":38},"2027-05-01",{"date":52,"type":38},"2039-12-01",{"name":5,"class":6}]